Product Images Levetiracetam

This text provides equations for calculating creatinine clearance with adjustments for age, weight, and gender. The first equation calculates the estimated creatinine clearance based on age and weight, with a correction factor for female patients. The second equation uses serum creatinine levels to estimate creatinine clearance.*

The text describes a figure (Figure 1) that shows the Responder Rate in Study 1. The Responder Rate is defined as a reduction of more than 50% in comparison to the baseline. The figure includes three bars, which correspond to three different treatments: Placebo (N=95), Levetiracetam 1000mg/day (N=37), and Levetiracetam 3000mg/day (N=101). The percentage of responders for each treatment is indicated in the figure, and a statistically significant result is highlighted with an asterisk.*

This is a figure (Figure 2) showing the Responder Rate in Study 2 for a medication called Levetiracetam. The Responder Rate is defined as a >50% reduction from baseline. The x-axis shows different levels of response (ranging from 0% to 45%), and the y-axis shows the percentage of participants. The figure compares the response rates for a placebo group (N=111) with two different doses of Levetiracetam (1000 mg/day and 2000 mg/day, N=106 and N=105 respectively). The figure indicates that the higher dose of Levetiracetam resulted in a statistically significant higher responder rate than the placebo group. No other information about the study or the medication is given.*

The text describes the responder rate in Study 3, where a 50% reduction from baseline was observed. It includes a figure displaying the responder rates in percentage for the placebo group (N=104) and the Levetiracetam 3000mg/day group (N=180). The figure shows that Levetiracetam was statistically significant compared to placebo as it resulted in a higher responder rate.*

The image shows a graph comparing the responder rate of patients who received placebo and those who received Levetiracetam medication. The y-axis represents the percentage of patients, and the x-axis represents the responder rate. The graph indicates that Levetiracetam medication had a statistically significant positive effect on more than 50% of the patients, whereas less than 20% of patients who received placebo medication had such effects.*

The text describes a graph or chart showing the responder rate for a study on participants with PGTC seizures. It shows the percentage of participants with greater than 50% reduction in seizure frequency per week. The graph indicates that the responder rate was statistically significant for a group receiving the drug Levetiracetam compared to a placebo group.*

This is a description of a medication with NDC (National Drug Code) 76494-528-12. It is a bottle containing 120 tablets of 250 mg each of Evertacetam, USP. The container should be dispensed in a light-resistant container with a child-resistant closure. The enclosed package insert should be reviewed for dosage information. The medication should be stored between 20-25°C (68-77°F) with excursions permitted 10-30°C (50-86°F). It is manufactured by Hefang Hushai Pharmaceutical Co. Ltd. in China for Proston Pharmaceutical in Cranbury, NI, USA. This medication was issued in February 2015 with an Expiration date (Ex) that is not provided in the text.*

This is a medication for which the National Drug Code is 76494-529-12. It is available in tablet form with 120 tablets in a bottle. Each tablet contains 500mg of Levetiracetam. The medication needs to be dispensed in a container that is resistant to light and has a child-resistant closure. The enclosed package insert contains dosage information. The recommended storage temperature is between 20-25°C (68-77°F) with permissible excursion up to 10-15°C-30°C (59-86°F). The medication is manufactured in China by Thefang Huahai PharmacsutialCo, Ltd for Prestion Phamaceutile based in Cranbusy, NI 08512, USA. The lot number and date of issuance are also mentioned, but ineligible characters make it unreadable.*

This is a medication with NDC code 76494-530-12. The medication comes in a container with a child-resistant enclosure and should be dispensed in a light-resistant container. Each tablet of the medication contains 750 mg of evetracetam, USP. Dosage information is enclosed in the package insert. The medication should be stored at a temperature between 20-25°C (88-77°F), with excursions permitted at 10-15°C-30°C (53-86°F). The manufacturer of the medication is Iregang e Pramacestical Co. Ltd located in Hangzhou, Zhejiang, China with a subsidiary in Cranbury, NJ, USA. There is also information about the lot and expiration dates of the medication.*

This is a description of medication in tablet form with NDC 76494-531-06 as the identifier. The tablets contain 1000mg of evetiractam, USP and come in a light-resistant container with child-resistant closure. Dosage information can be found in the package insert enclosed. The medication should be stored at 20-25°C (68-77°F) with excursions permitted from 1015-30°C (59-86°F), which is considered a Controlled Room Temperature in accordance with USP regulations. The medication is manufactured by Ihefang Huahai Pharmaceutical Co, Lid located in Xungiao, Linha, Zhejiang 317024, China and distributed by Prinston Pharmaceutical Inc. in Cranbury, NJ. Lot and expiration numbers are not available.*